Please note: This event is now online only due to COVID restrictions in Victoria
You are invited to join BioMelbourne Network for our upcoming BioSymposium: Advancements in Precision Medicine – Opportunities, Challenges and Economics, sponsored by the State Government of Victoria, CSIRO, SeerPharma, Prime Accounting and Business Advisory and Honan Insurance Group.
The one-size-fits-all approach of conventional medicine is being challenged by rapid technological advancements in precise and personalised medicine which will continue to play a transformative role in the future of healthcare, leading to better outcomes for patients as well as health professionals, carers, and the broader sector. It will impact every area of HealthTech development including research, clinical trials, data and evidence, commercialisation, business models, payers, regulatory and reimbursement processes and encompasses legal, ethical, and social matters.
Aside from the technological advancement, changes to the patient journey mean the way patient-centricity is viewed must change. This impacts the whole development process, which is driven by the patient, with precision medicine encompassing prevention and treatment of disease based on a patient’s genetic makeup, environment and lifestyle.
Technologies are evolving with increased collaboration, data, digital engagement of patients and machine learning. Changes were happening already but has this pace of change been accelerated by the pandemic and has the willingness of regulators to approve highly innovative medicines been affected for non-COVID related innovative medicines? Precision medicines were already challenging the regulatory and reimbursement process.
Across 4 sessions, local and international speakers will provide insight into the opportunities and challenges they face in various areas of precision medicine, including research, regulations, reimbursement, clinical trials, health economics and commercialisation.
This event will take place via a live-stream split into four recorded sessions (available post-event for attendees).
- Session 1: Barriers and opportunities in clinical research
- Session 2: Efficiency and access in clinical trials
- Session 3: Aligning Precision Medicine with the regulation and reimbursement processes
- Session 4: Commercialisation, the pathway to market
More information on sessions and speakers can be found below and here.
Who Should Attend
- Business leaders
- Product developers
- Industry experts across biotechnology, pharmaceuticals and health innovation
- Friday 3rd September 2021
- 9.00am – 5.00pm
- Live stream: Zoom Webinar. A link to join will be shared via email prior to the event.
- Price (BioMelbourne Network members): $50 online
- Price (non-members): $80 online
Prices include GST. To check if your organisation is a member click here
A full refund will be given up to 7 days prior to the event. No refunds will be given within 7 days of the event. COVID-19- postponement or change of date: Full refund or ticket changed to new date
Thank you to our sponsors
Sessions and speakers
Session 1: Barriers and opportunities in clinical research
Translational research has been revolutionised by precision medicine with therapeutic choices being patient-centric and driven by the identification of predictive biomarkers reducing the use of both ineffective therapies and adverse patient effects. Combining ‘omics’ and pre-clinical study models is accelerating the incorporation of precision medicine into clinics.
The speakers in this session will provide insights into some of the research being done, looking at barriers, opportunities and benchmarks and presenting some case studies and projects from across Australia. Speakers will join us from the Victorian Comprehensive Cancer Centre, the Walter and Eliza Hall Institute of Medical Research and the Murdoch Children’s Research Institute.
Dr Mark Buzza
Head of Clinical Research Programs, Victorian Comprehensive Cancer Centre
Professor Clare L Scott MBBS PhD FRACP FAHMS
Professor of Gynaecological Cancer, University of Melbourne,
Joint Head, Clinical Translation Centre and Laboratory Head, Walter and Eliza Hall Institute of Medical Research
Medical Oncologist, Peter MacCallum Cancer Centre, Royal Melbourne and Royal Women's Hospitals
Professor Melissa Wake
Paediatrician FAHMS MBChB FRACP MD GradDip Obst & Gynae
Scientific Director, GenV & Group Leader, Prevention Innovation – Murdoch Children’s Research Institute
Professorial Fellow, Department of Paediatrics, The University of Melbourne
Honorary Professor, Liggins Institute, The University of Auckland
Professor Clara Gaff, Executive Director, Melbourne Genomics
Session Chair: Dr Keith McLean, Board Director, BioMelbourne Network
Session 2: Efficiency and access in clinical trials
Data and patient populations are driving change in clinical trial designs with the availability of real-work data and increasing integration of AI and algorithms to interpret the data, improving efficiencies and reducing risks leading to improved healthcare design, development and delivery.
In this session speakers will discuss their clinical trial work, use of AI and de-centralised trials.
Michelle Gallagher, Chief Executive Officer, Opyl Ltd
Kevin Wightman, Senior Director, Corporate and Business Development, Illingworth Research Group
Scott Scarola, VP Operations Management Decentralized Solutions Team, Syneos Health
Daniel Reid, Client Manager Corporate Insurance & Risk Solutions (Industry Leader – Life Science & Biotech)
Honan Insurance Group
Session Chair: Michelle Peake, SeerPharma
Session 3: Aligning precision medicine with the regulation and reimbursement processes
Changes to the research and clinical trial processes have challenged the evidence to support regulatory and reimbursement submissions.
The willingness of regulators and payers to approve innovative therapies is being tested. Therapies are being assessed on limited data, while regulators are under pressure get safe and effective therapies to patients without delay.
The focus for this session will be on costs and reimbursement, gaining regulatory and the health economics of personalised medicine.
Nicole Millis, Chief Executive Officer, Rare Voices Australia
Carlo Montagner, Chief Executive Officer, Specialised Therapeutics
Dr Evan B. Siegel, M.Phil., Ph.D. President and CEO, Ground Zero Pharmaceuticals, Inc.
Professor Cathy Mihalopoulos - Chair and Head, Deakin Health Economics; Faculty of Health, Deakin University
Session Chair: Andrew Carter, Managing Director, Commercial Eyes
Session 4: Commercialisation, the pathway to market
The pathway through development to market for medicine is long and complex and for precision medicine many or all these stages need to be adjusted for the requirements of either individual patients or subgroups of patients.
In this session our speakers will share their insights and experiences with this journey and present case studies outlining their commercialisation pathway.
Belinda Wood, Senior Director Government Affairs ANZ, Gilead Sciences
Dr Gabriel Liberatore – Group Chief Operating Officer, Telix Pharmaceuticals Limited
Sarah Rickwood, Vice President, EMEA Marketing and Thought Leadership, IQVIA
Session Chair: Simone Quin, Prime Accounting and Business Advisory